Detalhe da pesquisa
1.
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.
Cardiovasc Diabetol
; 23(1): 104, 2024 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-38504284
2.
Overburden of rare ALMS1 deleterious variants in Chinese early-onset type 2 diabetes with severe insulin resistance.
Diabetes Metab Res Rev
; 40(4): e3788, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38546151
3.
The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: A systematic review and meta-analysis.
Pharmacol Res
; 203: 107157, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38531504
4.
Efficacy and safety of tirzepatide in people with type 2 diabetes by baseline body mass index: An exploratory subgroup analysis of SURPASS-AP-Combo.
Diabetes Obes Metab
; 26(4): 1454-1463, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38302718
5.
Differential effect of interventions in patients with prediabetes stratified by a machine learning-based diabetes progression prediction model.
Diabetes Obes Metab
; 26(1): 97-107, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37779358
6.
Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once-weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1-5, 7-10 and SUSTAIN China.
Diabetes Obes Metab
; 26(1): 233-241, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37822270
7.
Baseline Urine Albumin-to-Creatinine Ratio is Associated With Decline of Estimated Glomerular Filtration Rate in Patients Newly Diagnosed With Type 2 Diabetes Mellitus: An Observational 5-year Cohort Study.
Endocr Pract
; 30(2): 107-112, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37925156
8.
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop.
Cardiovasc Diabetol
; 22(1): 277, 2023 10 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37833776
9.
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
Cardiovasc Diabetol
; 22(1): 59, 2023 03 16.
Artigo
Inglês
| MEDLINE | ID: mdl-36927451
10.
Distribution of autoantibodies to insulinoma-associated antigen-2 and zinc transporter 8 in type 1 diabetes and latent autoimmune diabetes: A nationwide, multicentre, cross-sectional study.
Diabetes Metab Res Rev
; 39(2): e3592, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36401613
11.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and the Risk of Fracture: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Calcif Tissue Int
; 113(2): 175-185, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37099141
12.
A multicentre, randomized, double-blind, parallel, active- and placebo-controlled Phase 3 clinical study of the glucokinase activator PB-201 in treatment-naive patients with type 2 diabetes mellitus: A study protocol.
Diabetes Obes Metab
; 25(3): 649-655, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36309971
13.
Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double-blind, placebo-controlled, parallel study.
Diabetes Obes Metab
; 25(7): 1839-1848, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36864540
14.
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross-sectional data.
Diabetes Obes Metab
; 25 Suppl 1: 5-12, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36811222
15.
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
Diabetes Obes Metab
; 25(5): 1229-1240, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36594724
16.
New insights into the treatment of obesity.
Diabetes Obes Metab
; 25(8): 2058-2072, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37055715
17.
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Diabetes Obes Metab
; 25(8): 2084-2095, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37013892
18.
Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register.
Diabetes Obes Metab
; 25(1): 208-221, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36082513
19.
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER study.
Diabetes Obes Metab
; 25(7): 1890-1899, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36906837
20.
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial.
Diabetes Obes Metab
; 25(12): 3671-3681, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37661308